New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
10:07 EDTTER, RYN, SNI, JNS, CY, SUSQ, VCBI, NE, GMT, MTG, SKUL, MDT, UAL, F, CYN, IAG, FLS, CP, GS, FLEXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Canadian Pacific (CP) downgraded to Sell from Hold at Canaccord... City National (CYN) downgraded to Neutral from Buy at SunTrust... Flextronics (FLEX) downgraded to Neutral from Buy at UBS... Flowserve (FLS) downgraded to Buy from Strong Buy at CL King... Ford (F) downgraded to Equal Weight from Overweight at Barclays... Goldman Sachs (GS) downgraded to Hold from Buy at Deutsche Bank... IAMGOLD (IAG) downgraded to Neutral from Buy at BofA/Merrill... Janus Capital (JNS) downgraded to Sell from Neutral at Citigroup... Medtronic (MDT) downgraded to Hold from Buy at Wunderlich... Noble Corp. (NE) downgraded to Hold from Buy at Jefferies... Scripps Networks (SNI) downgraded to Underweight from Equal Weight at Morgan Stanley... Skullcandy (SKUL) downgraded to Neutral from Overweight at Piper Jaffray... United Continental (UAL) downgraded to Underperform from Neutral at BofA/Merrill... Virginia Commerce (VCBI) downgraded to Market Perform from Outperform at FBR Capital... Rayonier (RYN) downgraded to Sector Perform from Outperform at RBC Capital... MGIC Investment (MTG) downgraded to Underperform from Neutral at Macquarie... Susquehanna (SUSQ) downgraded to Hold from Buy at BB&T... Teradyne (TER)downgraded to Hold from Buy at Craig-Hallum... United Continental (UAL) downgraded to Neutral from Buy at Buckingham... GATX Corp. (GMT) downgraded to Outperform from Strong Buy at Raymond James... Cypress Semiconductor (CY) downgraded to Hold from Buy at Wunderlich.
News For CP;CYN;FLEX;FLS;F;GS;IAG;JNS;MDT;NE;SNI;SKUL;VCBI;RYN;MTG;SUSQ;TER;GMT;CY;UAL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 18, 2015
07:27 EDTGSFreeport seeks funding from Blackstone, Apollo, Reuters says
Freeport McMoRan (FCX) has hired Goldman Sachs (GS) and Barclays (BCS) to find private equity firms willing to finance certain of its energy projects and asset developments, reports Reuters, citing people familiar with the matter. Freeport is in talks with Blackstone (BX), Apollo (APO), and Warburg Pincus about a potential partnership. The sources say the firm may be seeking "several billion dollars," though discussions are in "very early" stages. Reference Link
06:09 EDTGSGoldman Sachs prices 6M shares of specialty lending arm, WSJ reports
According to a source, late yesterday, Goldman Sachs priced 6M shares of Goldman Sachs BDC, its specialty lending arm, at $20 per share with the shares set to begin trading today, The Wall Street Journal reports. Shares of Goldman Sachs BDC will trade under the ticker symbol "GSBD." Reference Link
05:55 EDTCYStocks with implied volatility movement; MGM CY
Subscribe for More Information
05:39 EDTMDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:00 EDTCYOptions Update; March 17, 2015
iPath S&P 500 VIX Short-Term Futures down 11c to 27.30. Option volume leaders: AAPL RIG MGM HTZ TWTR TSLA CY KO NFLX C according to Track Data.
14:13 EDTFMorgan Stanley questions GM capital allocation plan
Subscribe for More Information
10:02 EDTSNIHigh option volume stocks
High option volume stocks: NGL ARCO ENR OIL SNI ESPR CYH WIN CRZO DISH
09:13 EDTFMSFT announced several partnerships with industry leaders
At Microsoft Convergence 2015, Microsoft (MSFT) announced several new partnerships with industry leaders. Teaming up with Microsoft, Ford Motor (F) will expand connected services for customers around the world with the creation of the Ford Service Delivery Network. Microsoft also announced several partnerships and collaboration agreements with leading companies in sales, field service, digital transaction management and analytics markets. Microsoft and InsideSales.com will offer its complete sales acceleration platform. Microsoft and FieldOne Systems announced their agreement to bring the FieldOne Sky field service management solution into the Microsoft Dynamics global independent software vendor program. DocuSign and Microsoft announced that the two companies will bring DocuSign's Digital Transaction Management platform to Microsoft Dynamics CRM users. Microsoft also announced the acquisition of intellectual property from Fusion Software which will add Voice of the Customer capabilities to Microsoft Dynamics.
09:06 EDTUALBoeing delivers first 787-9 Dreamliner assembled at North Charleston facility
Subscribe for More Information
08:49 EDTSNIScripps acquisition of Polish business difficult to understand, say Bernstein
Subscribe for More Information
07:48 EDTSNIScripps to meet with BBC Trust over GBP500M offer for UKTV stake, Guardian says
Subscribe for More Information
March 16, 2015
13:16 EDTMDTAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
09:01 EDTCPCanadian Pacific renews share repurchase program
Subscribe for More Information
07:30 EDTMDTAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
06:04 EDTSNIScripps Networks to host conference call
Subscribe for More Information
05:19 EDTSNIScripps Networks to acquire controlling interest in Polish TV operator TVN
Scripps Networks has entered into an agreement to acquire a 52.7% interest in Polandís premier multi-platform media company, TVN. The company has agreed to acquire the stake from ITI and Canal+ Group for an all-cash consideration of EUR 584M. Scripps Networks Interactive will also assume EUR 840M of debt. The agreement is subject to regulatory approvals. Following completion, Scripps Networks Interactive will launch a mandatory public tender offer to further increase its ownership interest in TVN, as required under Polish law.
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use